Search

Author/Creator van der Weele, Wilfred

1. Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice. (14th February 2019)

Authors:
Layegh, Zohra; Ruwaard, Jill; Hebing, Renske C. F.; l' Ami, Merel J.; van der Weele, Wilfred; Nurmohamed, Mike T.; Krieckaert, Charlotte; Wolbink, Gertjan
Journal:
International journal of rheumatic diseases
Issue:
Volume 22:Number 5(2019)
Page Start:
869
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells. (10th June 2022)

Authors:
Opdam, Merel A A; de Leijer, J H; den Broeder, Nathan; Thurlings, Rogier M; van der Weele, Wilfred; Nurmohamed, Michael T; Kok, Marc R; van Bon, Lenny; Ten Cate, David F; Verhoef, Lise M; den Broeder, Alfons A
Journal:
Rheumatology
Issue:
Volume 62:Number 1(2023)
Page Start:
330
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial. (November 2019)

Authors:
Verhoef, Lise M; den Broeder, Nathan; Thurlings, Rogier M; van der Laan, Willemijn H; van der Weele, Wilfred; Kok, Marc R; Bernelot Moens, Hein J; Woodworth, Thasia G; van den Bemt, Bart J F; van den Hoogen, Frank H J; den Broeder, Alfons A
Journal:
Lancet
Issue:
Volume 1:Number 3(2019)
Page Start:
e145
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗